title: No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38.
abstract: OBJECTIVE
  To determine whether genotypes at 2 major loci associated with late age-related macular degeneration (AMD), complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), influence the relative benefits of Age-Related Eye Disease Study (AREDS) supplements.
  
  
  METHODS
  Unplanned retrospective evaluation of a prospective, randomized, placebo-controlled clinical trial of vitamins and minerals for the treatment of AMD.
  
  
  METHODS
  AREDS participants (mean age, 69 years) who were at risk of developing late AMD and who were randomized to the 4 arms of AREDS supplement treatment.
  
  
  METHODS
  Analyses were performed using the Cox proportional hazards model to predict progression to late AMD (neovascular or central geographic atrophy). Statistical models, adjusted for age, gender, smoking status, and baseline AMD severity, were used to examine the influence of genotypes on the response to therapy with 4 randomly assigned arms of AREDS supplement components: placebo, antioxidants (vitamin C, vitamin E, β-carotene), zinc, or a combination.
  
  
  METHODS
  The influence of the genotype on the relative treatment response to the randomized components of the AREDS supplement, measured as progression to late AMD.
  
  
  RESULTS
  Of the 1237 genotyped AREDS participants of white ethnicity, late AMD developed in 385 (31.1%) during the mean follow-up of 6.6 years. As previously demonstrated, CFH genotype (P = 0.005), ARMS2 (P< 0.0001), and supplement were associated individually with progression to late AMD. An interaction analysis found no evidence that the relative benefits of AREDS supplementation varied by genotype. Analysis of (1) CFH rs1061170 and rs1410996 combined with ARMS2 rs10490924 with the 4 randomly assigned arms of AREDS supplement and (2) analysis of the combination of CFH rs412852 and rs3766405 with ARMS2 c.372_815del443ins54 with the AREDS components resulted in no interaction (P = 0.06 and P = 0.45, respectively, before multiplicity adjustment).
  
  
  CONCLUSIONS
  The AREDS supplements reduced the rate of AMD progression across all genotype groups. Furthermore, the genotypes at the CFH and ARMS2 loci did not statistically significantly alter the benefits of AREDS supplements. Genetic testing remains a valuable research tool, but these analyses suggest it provides no benefits in managing nutritional supplementation for patients at risk of late AMD.
authors: Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: echew@nei.nih.gov.
authors: Emily Y
authors: EY
authors: Chew
authors: Casey Eye Institute, Oregon Health & Science University, Portland, Oregon.
authors: Michael L
authors: ML
authors: Klein
authors: The EMMES Corporation, Rockville, Maryland.
authors: Traci E
authors: TE
authors: Clemons
authors: Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
authors: Elvira
authors: E
authors: Agrón
authors: Neurobiology-Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
authors: Rinki
authors: R
authors: Ratnapriya
authors: Oregon Retina, LLP, Eugene, Oregon; Department of Biology, University of Oregon, Eugene, Oregon; and Casey Eye Institute, Oregon Health & Science University, Portland, Oregon.
authors: Albert O
authors: AO
authors: Edwards
authors: Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan.
authors: Lars G
authors: LG
authors: Fritsche
authors: Neurobiology-Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
authors: Anand
authors: A
authors: Swaroop
authors: Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan.
authors: Gonçalo R
authors: GR
authors: Abecasis
mesh_terms: D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage; D017242:Complement Factor H / Q000235:genetics; D019587:Dietary Supplements; D005260:Female; D005838:Genotype; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies; D011506:Proteins / Q000235:genetics*; D012189:Retrospective Studies; D014815:Vitamins / Q000008:administration & dosage; D017967:Zinc Compounds / Q000008:administration & dosage
chemical_list: C514392:ARMS2 protein, human; D000975:Antioxidants; C493495:CFH protein, human; D011506:Proteins; D014815:Vitamins; D017967:Zinc Compounds; D017242:Complement Factor H